We use cookies to ensure that we give you the best experience on our website. By continuing to browse this repository, you give consent for essential cookies to be used. You can read more about our Privacy and Cookie Policy.

Durham Research Online
You are in:

Targeting the thioredoxin system in the treatment of certain cancers.

Todd, A. and Anderson, R.J. and Pickles, G. and Groundwater, P.W. (2010) 'Targeting the thioredoxin system in the treatment of certain cancers.', The pharmaceutical journal., 284 . pp. 243-244.


The fourth and final science article on cancer treatments reviews the thioredoxin system and its association with cancer, and how it offers a new therapeutic target for anticancer drug design. The most stidied thioredoxin is the classic cytosolic thioredoxin (Trx1), which is the main focus of this article. Two irreversible thioredoxin inhibitors are in development, Px-12 (1-methylpropyl 2-imidazolyl disulphide) and PMX-464 (formerly AW464).

Item Type:Article
Keywords:Antineoplastics, Breast neoplasms, Drug development, Homeostasis, Gastrointestinal neoplasms, Colorectal neoplasms, Liver neoplasms, Review.
Full text:Full text not available from this repository.
Publisher Web site:
Record Created:28 Jun 2012 11:05
Last Modified:05 Dec 2012 12:29

Social bookmarking: del.icio.usConnoteaBibSonomyCiteULikeFacebookTwitterExport: EndNote, Zotero | BibTex
Look up in GoogleScholar | Find in a UK Library